Novozymes is the world leader in bioinnovation, producing a wide range of industrial enzymes, microorganisms, and biopharmaceutical ingredients.
February 26 2014
Today Novozymes A/S held its Annual Shareholders’ Meeting.
February 10 2014
On February 17, 2014, Novozymes will initiate a stock buyback program as announced in Company announcement No. 29 of December 10, 2013.
The BioAg Alliance will discover, develop and sell microbial solutions that enable farmers worldwide to increase crop yields with less input
I dag har Novozymes A/S afholdt ordinær generalforsamling.
Den 17. februar 2014 vil Novozymes påbegynde et aktietilbagekøbsprogram, således som offentliggjort i selskabsmeddelelse nr. 29 af 10. december 2013.
The BioAg Alliance vil forske i, udvikle og sælge mikrobielle løsninger, der gør det muligt for landmænd verden over at øge høstudbyttet med brug af færre ressourcer.
The European Commission has granted marketing approval to GlaxoSmithKline’s new type 2 diabetes medicine, Eperzan® (albiglutide). The drug uses albumin technology from Novozymes to extend the drug’s presence in the patient’s body.
March 31 2014
Novozymes LpHera® boosts yields during liquefaction while securing significant chemical, water and energy savings.
February 28 2014
Novozymes is ranked as the most sustainable company in the biotechnology sector in The Sustainability Yearbook 2014.
January 22 2014
| Copyright © 2014 Novozymes. All Rights Reserved.